Navigation Links
FASgen Announces New Discovery for Treatment of Stroke
Date:12/20/2007

BALTIMORE, Dec. 20 /PRNewswire/ -- FASgen is pleased to announce the recent publication of important results from research into a potential treatment for stroke using one of FASgen's proprietary compounds, C75. The Company is a leader in the research in the field of FASi (fatty acid synthase inhibition). One area of that research has been for the treatment of metabolic disease disorders, including obesity. As the regulation of appetite is centered in the hypothalamus in the brain, research was undertaken to evaluate the safety of the Company's compounds in the brain. An unexpected and significant discovery resulted when the studies demonstrated not only that the compounds were non-toxic in the brain, but also they had the positive effect of providing significant neuroprotection in the case of ischemic stroke. In the stroke models tested, the Company's compound C-75 reduced AMPK levels and resulted in neuroprotection by reduced stroke damage, even when administered poststroke. These remarkable findings were recently published in the article, "Neuroprotective Effects of Adenosine Monophosphate-Activated Protein Kinase Inhibition and Gene Deletion in Stroke," McCullough et al, Stroke 2007, 38; 2992-2999 (December 11, 2007).

About FASgen, Inc.: FASgen, Inc. is a drug development company founded in 2000 by four distinguished Johns Hopkins researchers to create new therapeutic products based on the selective inhibition of fatty acid biosynthesis. The Company has the exclusive license from Johns Hopkins to more than 15 years of research in the field, which research continues under a sponsored research agreement with the University.

The Company has designed and synthesized many compounds that selectively inhibit fatty acid biosynthesis. One group of these compounds holds great promise for new highly specific therapeutics for cancer; additional compounds have the potential of specific therapeutics for obesity and related metabolic disorders; and, an additional group of compounds have the potential of specific therapeutics for TB, including multiple drug resistant TB (MDR-TB) and latent TB infections that affect one third of the world's population. For more information, visit FASgen's website at http://www.fasgen.com


'/>"/>
SOURCE FASgen, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. FASgen Announces Significant Milestone in Its Cancer Drug Development Program
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... , Feb. 9, 2016 The new report "Global ... Acuity Business Research & Consulting group reveals that the ... with a share of 38.9% in 2014 that translated into revenues ... , Europe , Asia-Pacific , ... and Africa . The global anti-bacterial market is ...
(Date:2/8/2016)... Cardiac Assist Devices - ... GlobalData,s Medical Devices sector report, " Cardiac Assist ... provides an overview of Cardiac Assist Devices currently ... information on the pipeline products with comparative analysis ... The report reviews major players involved in the ...
(Date:2/8/2016)... Cardiovascular Surgery Devices - Medical Devices ... Devices sector report, "Cardiovascular Surgery Devices - Medical ... Cardiovascular Surgery Devices currently in pipeline stage. ... report provides comprehensive information on the pipeline products ... stages of development. The report reviews major players ...
Breaking Medicine Technology:
(Date:2/9/2016)... ... February 10, 2016 , ... The Journal of Pain Research has ... field .” , As corresponding author Dr John F. Peppin says “Terminology matters, yet ... our chronic pain patients. ‘Chronic cancer pain’ and ‘chronic non-cancer pain’ are replete ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... service to expand access to affordable hearing aids , increase industry transparency, ... individuals in the United States. , “For the average consumer, the hearing aid ...
(Date:2/9/2016)... ... , ... Two renowned photographers, Robert Caplin (New York, NY) and Peter Lockley ... 14-19, 2016, hosted by Four Seasons Resort Maui at Wailea as part of the ... 2015, the Maui Photo Expedition workshop will once again consist of on-location ...
(Date:2/9/2016)... California (PRWEB) , ... February 09, 2016 , ... i2i ... one of the highest preliminary data vendors in the latest KLAS report, Population Health ... i2i has led the developing market for population health management (PHM). The latest ...
(Date:2/8/2016)... N.J. (PRWEB) , ... February 08, 2016 , ... ... cancer patients, has officially launched the Multiple Myeloma Heroes Awards event , which ... or in the lives of patients with MM. The MM Heroes Awards nomination ...
Breaking Medicine News(10 mins):